{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:30:38Z","timestamp":1765837838045,"version":"3.40.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III","award":["FIS PI10\/01758"],"award-info":[{"award-number":["FIS PI10\/01758"]}]},{"name":"Fondos Europeos de Desarrollo Regional (FEDER)"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.schres.2016.05.011","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T01:43:49Z","timestamp":1464399829000},"page":"272-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline"],"prefix":"10.1016","volume":"176","author":[{"given":"Maria P.","family":"Garcia-Portilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Garcia-Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Sarramea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-2602","authenticated-orcid":false,"given":"Gonzalo","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Diaz-Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Bobes-Bascaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Al-Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edorta","family":"Elizagarate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar A.","family":"Saiz Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-4033","authenticated-orcid":false,"given":"Julio","family":"Bobes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2016.05.011_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.genhosppsych.2010.11.005","article-title":"A manic episode in a 64-year-old man: an adverse effect of varenicline","volume":"33","author":"Ahmed","year":"2011","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/2045125311430111","article-title":"Varenicline-induced psychotic depressive episode in a patient with bipolar disorder","volume":"2","author":"Annagur","year":"2012","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"16","key":"10.1016\/j.schres.2016.05.011_bb0015","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"S0140-6736","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2016.05.011_bb0020","first-page":"1455","article-title":"The Fagerstr\u00f6m test for nicotine dependence in a Spanish sample","volume":"83","author":"Beco\u00f1a","year":"1998","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.schres.2016.05.011_bb0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0025-7753(03)73814-7","article-title":"A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton depression rating scale","volume":"120","author":"Bobes","year":"2003","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.schres.2016.05.011_bb0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2010.02.1030","article-title":"Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort","volume":"119","author":"Bobes","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.05.011_bb0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/15504263.2012.749559","article-title":"An open trial of relapse prevention therapy for smokers with schizophrenia","volume":"9","author":"Cather","year":"2013","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.schres.2016.05.011_bb0045","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.4088\/JCP.11r07410","article-title":"Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies","volume":"73","author":"Cerimele","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0050","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4088\/JCP.13m08756","article-title":"Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study","volume":"75","author":"Chengappa","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0055","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0025-7753(02)73419-2","article-title":"Spanish version of a scale for the assessment of mania: validity and reliability of the young mania rating scale","volume":"119","author":"Colom","year":"2002","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.schres.2016.05.011_bb0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0065","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.schres.2015.11.010","article-title":"Mortality in schizophrenia and bipolar disorder: clinical and serological predictors","volume":"170","author":"Dickerson","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14622200110073920","article-title":"A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia","volume":"3","author":"Evins","year":"2001","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0080","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.jcp.0000162802.54076.18","article-title":"A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia","volume":"25","author":"Evins","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.05.011_bb0085","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/01.jcp.0b013e3180ca86fa","article-title":"A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia","volume":"27","author":"Evins","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.05.011_bb0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00406-014-0556-y","article-title":"T. Kishi and N. Iwata: varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis","volume":"265","author":"Evins","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2016.05.011_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2013.285113","article-title":"Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorders: a randomized clinical trial","volume":"311","author":"Evins","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2016.05.011_bb0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1176\/appi.ajp.2007.07020326","article-title":"Exacerbation of schizophrenia by varenicline","volume":"164","author":"Freedman","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-0447.2009.01498.x","article-title":"Impact of substance use on the physical health of patients with bipolar disorder","volume":"21","author":"Garcia-Portilla","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2016.05.011_bb0110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijerph110100373","article-title":"Effectiveness of a multi-component smoking cessation support programme (McSCSP) for patients with severe mental disorders: study design","volume":"11","author":"Garcia-Portilla","year":"2013","journal-title":"Int. Environ. Res. Public Health"},{"key":"10.1016\/j.schres.2016.05.011_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0006-3223(02)01339-2","article-title":"A placebo controlled trial of bupropion for smoking cessation in schizophrenia","volume":"52","author":"George","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0120","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.biopsych.2007.11.002","article-title":"A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia","volume":"63","author":"George","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0125","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1176\/appi.ajp.2013.12121599","article-title":"Varenicline, smoking cessation and neuropsychiatric adverse events","volume":"170","author":"Gibbons","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0130","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"Hong","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0135","first-page":"349","article-title":"Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia","volume":"1","author":"Horst","year":"2005","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2016.05.011_bb0140","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/schbul\/sbp152","article-title":"Cigarette smoking and mortality risk in people with schizophrenia","volume":"37","author":"Kelly","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.05.011_bb0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00406-014-0551-3","article-title":"Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis","volume":"265","author":"Kishi","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2016.05.011_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.genhosppsych.2011.05.008","article-title":"Varenicline induces manic relapse in bipolar disorder","volume":"33","author":"Knibbs","year":"2011","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.2013.284985","article-title":"Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation","volume":"311","author":"Le Cook","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2016.05.011_bb0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.psychres.2011.04.018","article-title":"Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia","volume":"190","author":"Liu","year":"2011","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1300\/J374v03n03_09","article-title":"Medications development for the treatment of nicotine dependence in individuals with schizophrenia","volume":"3","author":"Montoya","year":"2007","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.schres.2016.05.011_bb0170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1579-2129(06)60269-3","article-title":"Assessment of behavioral dependence with the Glover-Nilsson test in smoking cessation treatment","volume":"41","author":"Nerin","year":"2005","journal-title":"Arch. Bronoconeumol."},{"key":"10.1016\/j.schres.2016.05.011_bb0175","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1399-5618.2009.00744.x","article-title":"Cigarette smoking is associated with suicidality in bipolar disorder","volume":"11","author":"Ostacher","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2016.05.011_bb0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15504263.2012.663675","article-title":"Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial","volume":"8","author":"Pachas","year":"2012","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.schres.2016.05.011_bb0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0165-1781(94)90093-0","article-title":"Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia","volume":"53","author":"Peralta","year":"1994","journal-title":"Psychiat. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0190","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1399-5618.2011.00944.x","article-title":"An online survey of tobacco use, intentions to quit, and cessation strategies among people living with bipolar disorder","volume":"13","author":"Prochaska","year":"2011","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2016.05.011_bb0195","article-title":"Efficacy and acceptability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis","author":"Roberts","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.schres.2016.05.011_bb0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eurpsy.2013.11.002","article-title":"EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness","volume":"29","author":"R\u00fcther","year":"2014","journal-title":"Eur. Psychiat."},{"key":"10.1016\/j.schres.2016.05.011_bb0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2013.285243","article-title":"Tobacco control 50years after the 1964 surgeon general's report","volume":"311","author":"Schroeder","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2016.05.011_bb0210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2016.05.011_bb0215","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","article-title":"Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder","volume":"119","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0220","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4088\/JCP.14lr09456","article-title":"Varenicline for smoking cessation in the bipolar patient","volume":"76","author":"Tofler","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0225","article-title":"Interventions for smoking cessation and reduction in individuals with schizophrenia (review)","volume":"2","author":"Tsoi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2016.05.011_bb0230","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2011.02.003","article-title":"Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study","volume":"129","author":"Weiner","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0235","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.11m07522","article-title":"A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder","volume":"73","author":"Williams","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.011_bb0240","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.schres.2013.06.032","article-title":"Varenicline modulates spatial working memory deficits in smokers with schizophrenia","volume":"149","author":"Wing","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.011_bb0245","first-page":"3045","article-title":"A review of varenicline's efficacy and tolerability in smoking cessation in subjects with schizophrenia","volume":"Suppl 4","author":"Yousefi","year":"2011","journal-title":"J. Addict. Res. Ther."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099641630233X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099641630233X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:58:19Z","timestamp":1718603899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099641630233X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":49,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S092099641630233X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.05.011","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}